Related News
Home 禄 Business 禄 Manufacturing
Glaxo's breast cancer drug gets second chance
Source: Agencies |
July 10, 2009, Friday
|
Print Edition
Print Edition
BRITAIN'S cost-effectiveness watchdog is to reconsider a decision blocking the use of GlaxoSmithKline's breast cancer drug Tyverb on the National Health Service.
The National Institute for Health Clinical Excellence (NICE), which assesses drugs for reimbursement on the state health service, had ruled in March that the treatment had limited benefits and was too expensive.
But parts of a Glaxo appeal against the decision have been upheld in the light of new supplementary NICE advice for the assessment of treatments in small patient populations with a short life expectancy, the agency said yesterday.
The move means Glaxo will have a fresh opportunity to make a full submission to NICE under the new end of life criteria.
The National Institute for Health Clinical Excellence (NICE), which assesses drugs for reimbursement on the state health service, had ruled in March that the treatment had limited benefits and was too expensive.
But parts of a Glaxo appeal against the decision have been upheld in the light of new supplementary NICE advice for the assessment of treatments in small patient populations with a short life expectancy, the agency said yesterday.
The move means Glaxo will have a fresh opportunity to make a full submission to NICE under the new end of life criteria.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
